Form 8-K - Current report:
SEC Accession No. 0001213900-22-076878
Filing Date
2022-12-01
Accepted
2022-12-01 16:15:23
Documents
14
Period of Report
2022-12-01
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea169519-8k_citiuspharma.htm   iXBRL 8-K 28157
2 PRESS RELEASE DATED DECEMBER 1, 2022 ea169519ex99-1_citiuspharma.htm EX-99.1 16417
3 GRAPHIC ex99-1_001.jpg GRAPHIC 10983
  Complete submission text file 0001213900-22-076878.txt   237878

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ctxr-20221201.xsd EX-101.SCH 3239
5 XBRL LABEL FILE ctxr-20221201_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE ctxr-20221201_pre.xml EX-101.PRE 22367
8 EXTRACTED XBRL INSTANCE DOCUMENT ea169519-8k_citiuspharma_htm.xml XML 3598
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 221438986
SIC: 2834 Pharmaceutical Preparations